# US 2010/0166846 A1 · Management of myoclonus with oral liposomal reduced glutathione

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166846 A1
- Document ID: US20100166846A1
- Status: Published application
- Kind: A1
- Application number: 12/649,698
- Filed: 2009-12-30
- Published: 2010-07-01
- Earliest claimed: 2008-12-31
- Inventors: F. Timothy Guilford
- Web page: https://patentgrep.com/patent/US20100166846A1

## CPC

- A61K 38/063: {Glutathione}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a composition and method for the management of myoclonus and myoclonus and other illnesses related to mold toxin exposure. The invention proposes the use of reduced glutathione encapsulated in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to facilitate treatment of myoclonus. The oral liposomal reduced glutathione is also proposed for the removal of mold toxin and to improve symptoms in disease states related to exposure to mold toxins. The invention proposes a method of treatment combining an orally administrable preparation of liposomal glutathione with an anti-fungal agent.

## Claims

### Claim 1

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:
administration of an oral liposomal preparation of reduced glutathione.

### Claim 2

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:
administration of an oral liposomal preparation of reduced glutathione formulated from said reduced glutathione in liposomal formulation being formulated in a process whose temperature does not exceed 50 degrees C., and which process utilizes mixing of a first container of lecithin and glycerin, and a second container of components of at least deionized water and glutathione (reduced) and upon mixing at a temperature not in excess of 50 degrees, said reduced glutathione in liposomal formulation thereby being capable of storage at room temperature for at least one month with at least 50% of original reduced glutathione.

### Claim 3

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:
administration of an oral liposomal preparation of reduced glutathione in a form which can be taken orally or absorbed across the mucosa of the nose, mouth, gastrointestinal tract.

### Claim 4

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:
administration of an oral liposomal preparation of reduced glutathione in a form which can be absorbed by topical application for transdermal administration.

### Claim 5

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:
administration of reduced glutathione by intravenous infusion

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method according to claims 1-5 further comprising:
administration of a pharmaceutical agent having anti-fungal properties.

### Claim 7 (depends on 1, 2, 3)

The method according to claims 1 through 3, further comprising:
intranasal administration of a pharmaceutical agent having anti-fungal properties.

### Claim 8

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:
administration of an oral liposomal preparation of reduced glutathione; and
administration of itraconazole.

### Claim 9

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:
administration of an oral liposomal preparation of reduced glutathione; and
administration of amphoteracin.

### Claim 10

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:
administration of an oral liposomal preparation of reduced glutathione; and
administration of fluconazole.

### Claim 11

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:
administration of an oral liposomal preparation of reduced glutathione; and
administration of voriconazole.

### Claim 12

A method of treatment for patients having myoclonus-related neurodegenerative disease as a result of mold toxin exposure comprising:
administration of an oral liposomal preparation of reduced glutathione; and
administration of voriconazole.

### Claim 13 (depends on 1)

The method according to claims 1, and 3 through 5, and 8 though 12, further comprising:
said oral liposomal preparation of reduced glutathione being formulated in a process whose temperature does not exceed 50 degrees C., and which process utilizes mixing of a first container of lecithin and glycerin, and a second container of components of at least deionized water and glutathione (reduced) and upon mixing at a temperature not in excess of 50 degrees, said reduced glutathione in liposomal formulation thereby being capable of storage at room temperature for at least one month with at least 50% of original reduced glutathione.
